WILMINGTON, Mass., Oct. 23, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
today stated that it has shipped over $600,000 in previously unannounced orders of
QS-H150 and QS-B220s to multiple customers in Europe, the Middle
East, and Africa. Customers
for the handheld and desktop explosives trace detectors include
airports, cargo companies, hotels, and petroleum industry
facilities.
"These shipments include orders that are a direct result of the
impressive list of certifications our QS-B220 has received in the
last year. Implant Sciences continues to increase its presence in
the aviation security market, and overall, about half of the units
shipped went to aviation security users," stated Implant Sciences'
Vice President of Sales and Marketing, Dr. Darryl Jones.
"Over the years, Implant Sciences' products have garnered a lot
of respect in the market segments we have served. For example, one
of these recent shipments is the fifth order from one of our
critical infrastructure customers," added Glenn D. Bolduc, President and CEO at Implant
Sciences. "As we expand our presence in the large aviation security
market, we look forward to building the same kind of success
there."
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology,
providing fast, accurate detection of trace amounts of a wide
variety of military, commercial, and homemade explosives. Built
with no radioactive materials and featuring a low-maintenance,
self-calibrating, and self-clearing design, the QS-H150 provides
very high levels of operational availability. The QS-H150 has been
proven to perform well in a wide variety of temperatures and
challenging environments, from humid jungles to dry, sand swept
deserts.
About the QS-B220 Desktop Explosives and Drugs Trace
Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives as well as illicit drugs. With
significantly lower maintenance requirements than competing
systems, the QS-B220 can be deployed for a much lower total cost of
ownership than other approved products. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCal™ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, STAC in
France, the German Ministry of the
Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland
Security Award for "Best Explosives Detection Solution". All
Implant Sciences products are recognized as Qualified
Anti-Terrorism Technologies by the Department of Homeland Security.
For further details on the Company and its products, please visit
the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
there is no guaranty that the Transportation Security
Administration (TSA) or any other U.S. or foreign government and
law enforcement agencies or commercial consumers will purchase any
of our explosives detection products or that any new products we
may develop will be accepted by the TSA or by such other
governments, agencies or consumers; economic, political and other
risks associated with international sales and operations could
adversely affect our sales; our business is subject to intense
competition and rapid technological change, and our success will
depend on our ability to develop and introduce new products; and
other risks and uncertainties described in our filings with the
Securities and Exchange Commission, including our most recent Forms
10-K, 10-Q and 8-K. Such statements are based on management's
current expectations and assumptions which could differ materially
from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implant-sciences-ships-over-600000-in-explosives-trace-detectors-to-customers-in-europe-the-middle-east-and-africa-887820479.html
SOURCE Implant Sciences Corporation